Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy.

The transvenous implantable cardioverter-defibrillator (ICD) experience in hypertrophic cardiomyopathy (HCM) now spans 20 years of reliably terminating potentially lethal ventricular tachyarrhythmia ([1][1]), and along with a matured sudden death risk stratification strategy, has resulted in